Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Alzheimer's drug VY7523 enters human safety trials

NCT ID NCT06874621

Ongoing Disease control Sponsor: Voyager Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing a new medicine called VY7523 in 52 people with early Alzheimer's disease. The goal is to see if the drug is safe and how it works in the brain. Some participants will get the drug, others a placebo, and the study lasts up to 12 months for the highest dose group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE (AD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER'S DISEASE (AD)

Contacts and locations

Locations

  • VYGR Site 124001

    Toronto, Ontario, M3B2S7, Canada

  • VYGR Site 124002

    Ottawa, Ontario, K1Z1G3, Canada

  • VYGR Site 124003

    Montreal, Quebec, H3G1H9, Canada

  • VYGR Site 124004

    Montreal, Quebec, H4A3T2, Canada

  • VYGR Site 840002

    Wellington, Florida, 33414, United States

  • VYGR Site 840003

    Stuart, Florida, 34997, United States

  • VYGR Site 840004

    The Villages, Florida, 32162, United States

  • VYGR Site 840005

    Delray Beach, Florida, 33445, United States

  • VYGR Site 840006

    Orlando, Florida, 32803, United States

  • VYGR Site 840007

    Decatur, Georgia, 30030, United States

  • VYGR Site 840008

    Stamford, Connecticut, 06905, United States

  • VYGR Site 840009

    Matthews, North Carolina, 28105, United States

  • VYGR Site 840010

    Lady Lake, Florida, 32159, United States

  • VYGR Site 840011

    Plymouth Meeting, Pennsylvania, 19462, United States

  • VYGR Site 840012

    Toms River, New Jersey, 08755, United States

  • VYGR Site 840014

    Miami, Florida, 33135, United States

  • VYGR Site 840015

    Miami, Florida, 33126, United States

  • VYGR Site 840016

    Orange, California, 92866, United States

  • VYGR Site 840018

    Los Angeles, California, 90033, United States

  • VYGR Site 840020

    Winter Park, Florida, 32789, United States

  • VYGR Site 840021

    Fort Myers, Florida, 33912, United States

  • VYGR Site 840022

    San Francisco, California, 94158, United States

  • VYGR Site 840024

    Miami, Florida, 33137, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.